Free public records show Entrada Therapeutics, Inc. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Entrada Therapeutics, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: SEC EDGAR, Company filings, CIK 1689375. Retrieved 13 Nov 2026.
3 active studies led by Entrada Therapeutics, Inc., of 4 in all
Source: ClinicalTrials.gov, Studies with Entrada Therapeutics, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1689375.
Studies Entrada Therapeutics, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Entrada Therapeutics, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Entrada Therapeutics, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Entrada Therapeutics, Inc. is in.
Stories on the topics Entrada Therapeutics, Inc. works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read
The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
ReadSearch all reports for Entrada Therapeutics, Inc. All companies